PLASMA MALONDIALDEHYDE IN TYPE-1 AND TYPE-2 DIABETIC-PATIENTS

被引:140
|
作者
GALLOU, G [1 ]
RUELLAND, A [1 ]
LEGRAS, B [1 ]
MAUGENDRE, D [1 ]
ALLANNIC, H [1 ]
CLOAREC, L [1 ]
机构
[1] HOP SUD,CLIN MED LAB F,F-35056 RENNES,FRANCE
关键词
MALONDIALDEHYDE; LIPID PEROXIDATION; INSULIN-DEPENDENT DIABETES-MELLITUS; NON-INSULIN-DEPENDENT DIABETES-MELLITUS; ANGIOPATHY;
D O I
10.1016/0009-8981(93)90114-J
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Malondialdehyde, a marker of lipid peroxidation, was measured as thiobarbituric acid reactive substances (TBARS) in 117 diabetic patients and 53 controls. Patients were divided into groups and subgroups according to the type of diabetes (type 1 and type 2) and the existence or not of vascular complication (macro- or microangiopathy). Results showed that TBARS concentrations were significantly higher in type 1 (P < 0.0001) and type 2 (P < 0.001) diabetic patients than in the control group. The plasma TBARS concentrations in type 1 and type 2 diabetic patients did not differ significantly. Among the patients with vascular disease, type 2 diabetic patients with macroangiopathy had significantly higher TBARS concentrations than patients with no vascular complication (P < 0.05). Whichever the type of diabetes, there was no correlation between TBARS concentrations and glycaemic control: glycosylated haemoglobin, fasting blood glucose. This study confirmed the existence of lipid peroxidation disorders in diabetic patients.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 50 条
  • [1] INSULIN KINETICS IN TYPE-1 AND TYPE-2 DIABETIC-PATIENTS
    NAVALESI, R
    PACI, A
    PILO, A
    BENZI, L
    GIAMPIETRO, O
    TALLARIGO, L
    MATTEUCCI, E
    CECCHETTI, P
    MASONI, A
    DIABETOLOGIA, 1981, 21 (03) : 308 - 308
  • [2] MICROALBUMINURIA IN A POPULATION OF 653 TYPE-1 AND TYPE-2 DIABETIC-PATIENTS
    DESCAMPS, O
    BUYSSCHAERT, M
    KETELSLEGERS, JM
    HERMANS, M
    LAMBERT, AE
    DIABETES & METABOLISM, 1991, 17 (05): : 469 - 475
  • [3] PROXIMAL FEMUR DENSITY IN TYPE-1 AND TYPE-2 DIABETIC-PATIENTS
    BUYSSCHAERT, M
    CAUWE, F
    JAMART, J
    BRICHANT, C
    DECOSTER, P
    MAGNAN, A
    DONCKIER, J
    DIABETES & METABOLISM, 1992, 18 (01): : 32 - 37
  • [4] AUTONOMIC NERVE ANTIBODIES AND AUTONOMIC NERVE FUNCTION IN TYPE-1 AND TYPE-2 DIABETIC-PATIENTS
    SUNDKVIST, G
    LIND, P
    BERGSTROM, B
    LILJA, B
    RABINOWE, SL
    JOURNAL OF INTERNAL MEDICINE, 1991, 229 (06) : 505 - 510
  • [5] HALT OF THE PROGRESSION OF NEPHROPATHY IN TYPE-1 AND TYPE-2 DIABETIC-PATIENTS BY ANTIHYPERTENSIVE TREATMENT WITH NITRENDIPINE
    BRETZEL, RG
    BOLLEN, C
    MASER, E
    FEDERLIN, K
    KIDNEY INTERNATIONAL, 1992, 41 (02) : 479 - 480
  • [6] WINE FOR TYPE-2 DIABETIC-PATIENTS
    CHRISTIANSEN, C
    THOMSEN, C
    RASMUSSEN, O
    BALLE, M
    HAUERSLEV, C
    HANSEN, C
    HERMANSEN, K
    DIABETIC MEDICINE, 1993, 10 (10) : 958 - 961
  • [7] PLASMA-LIPOPROTEIN COMPOSITION IN TYPE-2 DIABETIC-PATIENTS
    MOLLER, A
    RASMUSSEN, L
    LEDET, T
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1987, 47 (07): : 731 - 738
  • [8] UNEXPLAINED DEATHS OF TYPE-1 DIABETIC-PATIENTS
    TATTERSALL, RB
    GILL, GV
    DIABETIC MEDICINE, 1991, 8 (01) : 49 - 58
  • [9] PLASMA-LIPID LEVELS AT DIAGNOSIS IN TYPE-2 DIABETIC-PATIENTS
    SOSENKO, JM
    KATO, M
    SOTO, R
    GOLDBERG, RB
    DIABETIC MEDICINE, 1993, 10 (09) : 814 - 819
  • [10] PREVENTION OF MACROANGIOPATHY IN TYPE-2 DIABETIC-PATIENTS
    CHARBONNEL, B
    LAURENT, C
    DIABETES & METABOLISM, 1994, 20 (3BIS) : 366 - 374